Focus: Ceribell is a medical device company specializing in fast EEG (electroencephalogram) systems for acute neurological diagnostics, primarily targeting delirium detection in intensive care settings. The company operates in the neurology and ophthalmology therapeutic areas with a focused device-based approach.
Profile data last refreshed 38m ago · AI intelligence enriched 1w ago
Hot — 42 jobs added in 30d
Net +25 (42 new, 17 removed). Aggressive expansion phase.
Ceribell offers growth-stage device commercialization opportunity with meaningful diagnostic impact, but career stability depends on successful market adoption and undisclosed financial health.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Ceribell
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Ceribell's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles